GARY ALAN SHANGOLD, M.D.
Medical Practice at Laurel Mountain Way, Califon, NJ
License number
New Jersey 74476
Category
Medical Practice
Type
Reproductive Endocrinology
Address
Address
14 Laurel Mountain Way, Califon, NJ 07830
Phone
(908) 439-9123
Professional information
Ceo At Integurx Therapeutics Llc
Position:
Vice-Chair, Board of Trustees at Association of Clinical Research Professionals, Chief Executive Officer at InteguRx Therapeutics LLC, President & Managing Member at Convivotech LLC
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Association of Clinical Research Professionals
since Jan 2012
-
Vice-Chair, Board of Trustees
InteguRx Therapeutics LLC
- Califon, NJ since May 2011
-
Chief Executive Officer
Convivotech LLC
since Jan 2006
-
President & Managing Member
Xanodyne Pharmaceuticals
Jan 2008 - Dec 2010
-
Chief Medical Officer and EVP, R&D
NovaDel Pharma
Dec 2002 - Dec 2005
-
President & CEO
American Academy of Pharmaceutical Physicians
- Apex, NC Apr 2004 - Apr 2005
-
President
Johnson & Johnson Pharmaceutical R&D
Mar 1999 - Dec 2002
-
VP, Regulatory Head of Drug Development
RW Johnson Pharmaceutical Research Institute
Jun 1996 - Mar 1999
-
Contraception Global Product Leader
RW Johnson Pharmaceutical Research Institute
Apr 1992 - Jun 1996
-
Sr. Director, Gynecologic & Reproductive Clinical Research
Serono Laboratories
Apr 1991 - Apr 1992
-
Medical Director, Obstetrics/Gynecology/Infertility
University of Chicago Pritzker School of Medicine
Aug 1983 - Mar 1991
-
Associate Professor, Obstetrics & Gynecology
Education:
University of Southern California 1981 - 1983
Fellowship, Reproductive Endocrinology University of Miami 1977 - 1981
Residency, Obstetrics & Gynecology Columbia University College of Physicians and Surgeons 1973 - 1977
M.D., Medicine University of Pennsylvania 1970 - 1973
B.A., Social Behavior
Fellowship, Reproductive Endocrinology University of Miami 1977 - 1981
Residency, Obstetrics & Gynecology Columbia University College of Physicians and Surgeons 1973 - 1977
M.D., Medicine University of Pennsylvania 1970 - 1973
B.A., Social Behavior
Dr. Gary Alan Shangold, Califon NJ - MD (Doctor of Medicine)
Specialties:
Reproductive Endocrinology & Infertility
Address:
14 Laurel Mountain Way, Califon 07830
(908) 439-9123 (Phone)
(908) 439-9123 (Phone)
Certifications:
Fertility & Reproductive Endocrinology, 1985, Obstetrics & Gynecology, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1977
U Miami/Jackson Meml Hosp
La Co/U Southern Calif Med
Columbia University / College of Physicians And Surgeons
Graduated: 1977
U Miami/Jackson Meml Hosp
La Co/U Southern Calif Med
Low Dose Estrogen Interrupted Hormone Replacement Therapy
US Patent:
6747019, Jun 8, 2004
Filed:
Apr 30, 2002
Appl. No.:
10/134455
Inventors:
Robert F. Casper - Toronto, CA
Gary A. Shangold - Califon NJ
Militza K. Ausmanas - Lake Forest IL
Gary A. Shangold - Califon NJ
Militza K. Ausmanas - Lake Forest IL
Assignee:
Jencap Research, Ltd. - Toronto
Ortho-McNeil Pharmaceutical, Inc. - Raritan NJ
Ortho-McNeil Pharmaceutical, Inc. - Raritan NJ
International Classification:
A61K 3156
US Classification:
514170
Abstract:
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 g per day of norgestimate.
Triphasic Oral Contraceptive
US Patent:
2001004, Nov 22, 2001
Filed:
Feb 13, 2001
Appl. No.:
09/782420
Inventors:
Gary Shangold - Califon NJ, US
Arkady Rubin - Brooklyn NY, US
David Upmalis - Newton PA, US
Arkady Rubin - Brooklyn NY, US
David Upmalis - Newton PA, US
International Classification:
A61K031/56
US Classification:
514/170000
Abstract:
A method of contraception in which an estrogen and desogestrel are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 g of 17-ethinylestradiol and in progestogenic activity to 0.065-0.75 of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen, provided that the progestin dose should increase from the first phase to the second phase to the third phase, that the progestin is desogestrel at a dose in each phase of between of from 0.05-1.0 mg/day and that the dosage of estrogen is kept constant in each phase.
Triphasic Oral Contraceptive
US Patent:
2005003, Feb 17, 2005
Filed:
Sep 21, 2004
Appl. No.:
10/945698
Inventors:
Gary Shangold - Califon NJ, US
Arkady Rubin - Brooklyn NY, US
David Upmalis - Newtown PA, US
Arkady Rubin - Brooklyn NY, US
David Upmalis - Newtown PA, US
International Classification:
A61K031/56
US Classification:
514170000
Abstract:
A method of contraception in which an estrogen and desogestrel are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 μg of 17α-ethinylestradiol and in progestogenic activity to 0.065-0.75 of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen, provided that the progestin dose should increase from the first phase to the second phase to the third phase, that the progestin is desogestrel at a dose in each phase of between of from 0.05-1.0 mg/day and that the dosage of estrogen is kept constant in each phase.
Triphasic Oral Contraceptive
US Patent:
6214815, Apr 10, 2001
Filed:
Jun 9, 1999
Appl. No.:
9/328764
Inventors:
Gary Shangold - Califon NJ
Arkady Rubin - Brooklyn NY
David Upmalis - Newtown PA
Arkady Rubin - Brooklyn NY
David Upmalis - Newtown PA
Assignee:
Ortho-McNeil Pharmaceuticals, Inc. - Raritan NJ
International Classification:
A61K 3156
US Classification:
514170
Abstract:
A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28. mu. g of 17. alpha. -ethinylestradiol and in progestogenic activity to 0. 065-0. 75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0. 25-1. 0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0. 35-2. 0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen.
Low Dose Estrogen Interrupted Hormone Replacement Therapy
US Patent:
7078394, Jul 18, 2006
Filed:
Mar 22, 2004
Appl. No.:
10/806613
Inventors:
Robert F. Casper - Toronto, CA
Gary A. Shangold - Califon NJ, US
Militza K. Ausmanas - Lake Forest IL, US
Gary A. Shangold - Califon NJ, US
Militza K. Ausmanas - Lake Forest IL, US
Assignee:
Duramed Pharmaceuticals, Inc. - Pomona NY
International Classification:
A61K 31/56
US Classification:
514170
Abstract:
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate.
Low Dose Estrogen Interrupted Hormone Replacement Therapy
US Patent:
7320970, Jan 22, 2008
Filed:
May 24, 2006
Appl. No.:
11/439171
Inventors:
Robert F. Casper - Toronto, CA
Gary A. Shangold - Califon NJ, US
Militza K. Ausmanas - Lake Forest IL, US
Gary A. Shangold - Califon NJ, US
Militza K. Ausmanas - Lake Forest IL, US
Assignee:
Duramed Pharmaceutials, Inc. - Cincinnati OH
Jencap Research Ltd. - Toronto, Ontario
Jencap Research Ltd. - Toronto, Ontario
International Classification:
A61K 31/56
US Classification:
514170
Abstract:
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate.
Low Dose Estrogen Interrupted Hormone Replacement Therapy
US Patent:
2010006, Mar 11, 2010
Filed:
Sep 8, 2009
Appl. No.:
12/555196
Inventors:
Robert F. CASPER - Toronto, CA
Gary A. SHANGOLD - Califon NJ, US
Militza K. AUSMANAS - Lake Forest IL, US
Gary A. SHANGOLD - Califon NJ, US
Militza K. AUSMANAS - Lake Forest IL, US
Assignee:
Duramed Pharmaceuticals, Inc. - Cincinnati OH
Jencap Research Ltd. - Toronto
Jencap Research Ltd. - Toronto
International Classification:
A61K 31/56, A61P 5/24
US Classification:
514182
Abstract:
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate.
Low Dose Estrogen Interrupted Hormone Replacement Therapy
US Patent:
2008018, Jul 31, 2008
Filed:
Nov 27, 2007
Appl. No.:
11/945986
Inventors:
Robert F. CASPER - Toronto, CA
Gary A. SHANGOLD - Califon NJ, US
Militza K. AUSMANAS - Lake Forest IL, US
Gary A. SHANGOLD - Califon NJ, US
Militza K. AUSMANAS - Lake Forest IL, US
Assignee:
Duramed Pharmaceuticals, Inc. - Cincinnati OH
Jencap Research Ltd. - Toronto
Jencap Research Ltd. - Toronto
International Classification:
A61K 31/565, A61P 19/10, A61P 9/00, A61P 25/28
US Classification:
514170
Abstract:
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate.